Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Mythic Therapeutics

Mythic Therapeutics to Present Updated Dose Escalation Data from Phase 1 KisMET-01 Study on MYTX-011 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Mythic Therapeutics
Via Business Wire
Mythic Therapeutics Presents Preclinical Data Demonstrating Potent Efficacy of MYTX-011 Across a Broad Range of Tumor Xenograft Models Harboring Clinically Relevant Mutations at the American Association for Cancer Research (AACR) Annual Meeting
From Mythic Therapeutics
Via Business Wire
Mythic Therapeutics Presents Initial Dose Escalation Data from Ongoing Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Mythic Therapeutics
Via Business Wire
Mythic Therapeutics to Present Data from Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Mythic Therapeutics
Via Business Wire
Mythic Therapeutics Announces Publication of Preclinical Data Highlighting the Differentiating Properties of MYTX-011 in Molecular Cancer Therapeutics
From Mythic Therapeutics
Via Business Wire
Mythic Therapeutics Presents Preclinical Data on MYTX-011, an Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the American Association for Cancer Research (AACR) Annual Meeting
From Mythic Therapeutics
Via Business Wire
Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer
From Mythic Therapeutics
Via Business Wire
Mythic Therapeutics Receives FDA Fast Track Designation for MYTX-011 for Patients with Non-Small Cell Lung Cancer (NSCLC) with cMET Overexpression
From Mythic Therapeutics
Via Business Wire
Mythic Therapeutics to Present New Preclinical Data on MYTX-011, Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Mythic Therapeutics
Via Business Wire
Mythic Therapeutics Presents Preclinical Data on Investigational cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 at American Association for Cancer Research (AACR) Annual Meeting
From Mythic Therapeutics
Via Business Wire
Mythic Therapeutics Announces First Subject Dosed in Phase 1 KisMET-01 Clinical Trial of cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
From Mythic Therapeutics
Via Business Wire
Gilles Gallant, BPharm, PhD, FOPQ, Receives the George R. Pettit Individual Input to the Field Award for 2022
From Mythic Therapeutics
Via Business Wire
Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer
From Mythic Therapeutics
Via Business Wire
Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing
From Mythic Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.